

The ChondroCelect Harvester™ receives CE mark approval

Leuven and Hasselt (BELGIUM) – November 2, 2009 – TiGenix (NYSE Euronext: TIG) and MedInvents announce that the ChondroCelect Harvester™ has received CE (Conformité Européenne) Mark approval. The ChondroCelect Harvester™ is a proprietary biopsy tool that will be provided to orthopedic surgeons for harvesting cartilage biopsies.

The registration of the ChondroCelect Harvester™ follows the recent approval of ChondroCelect in Europe as the first cell-based product for cartilage repair to have received a European marketing authorization. ChondroCelect consists of characterized cultured chondrocytes derived from the patient's own cartilage. The process of producing ChondroCelect starts with a small cartilage sample taken by a surgeon. The standardization of the biopsy procedure and the quality and consistency of the cartilage sample are important elements for the final quality of the ChondroCelect end product. The ChondroCelect Harvester is specifically designed to allow harvesting cartilage biopsies from the knee in an easy and consistent manner, avoiding damage to the surrounding tissue and underlying bone. The specific design and ease of use of the ChondroCelect Harvester™ is expected to set a new standard in cartilage biopsy taking.

The Harvester was invented by and developed in close collaboration with Dr. Yves Fortems, clinical advisor to the company, and the medical device company MedInvents, who will produce the device. The device will be provided to the orthopedic surgeons as part of the ChondroCelect biopsy kit.

Dr. Yves Fortems, inventor of the ChondroCelect Harvester™, comments: "In designing the Harvester, we have specifically focused on the ease-of-use of the device in combination with delivering a superior and consistent quality of the cartilage biopsy. The quality of the cartilage biopsy is known to be an important factor for the quality of the ChondroCelect product."

Dr. Jaak Janssens, Medical Advisor to MedInvents comments: "We are very pleased with this result of our collaboration with TiGenix' clinical and development team. What I admired the most was the combination of patient driven research, methodological scrutiny and business competence."

For more information, please contact:

TiGenix NV

Gil Beyen
Chief Executive Officer
Kris Motmans
Corporate Communications
T: +32 16 39 60 60
Investor@tigenix.com

MedInvents NV

Johan Janssens
Chief Operating Officer
T: +32 11 27 15 57
johan.janssens@medinvents.com

About TiGenix

Based in Leuven, Belgium, TiGenix NV (NYSE Euronext Brussels: TIG) is a biomedical company that focuses on 'Regenerating Motion'. The company is exploiting the power of Regenerative Medicine to develop durable treatments, validated through controlled clinical trials, for damaged and osteoarthritic joints.

TiGenix is developing a portfolio of products that address specific musculoskeletal problems. The lead indication among these is cartilage damage, which is a debilitating affliction affecting the mobility and functioning of patients. Western societies are characterised by ageing populations that place an increasing emphasis on high quality of life and life-long mobility, and, as such, cartilage problems represent a large and growing unmet medical need. Current therapies do not provide satisfying, long-term durable repair and TiGenix therefore believes there is a need for more effective treatments for cartilage damage.

About ChondroCelect

ChondroCelect®, the company's lead product for cartilage regeneration in the knee, is the first cell-based product that successfully completed the entire development track from research, over clinical development to central European registration as a medicinal product. ChondroCelect consists of characterised cultured chondrocytes derived from the patient's own cartilage and is used for autologous chondrocyte implantation (ACI), a surgical procedure to treat cartilage defects. Cartilage defects of the knee are very common, and the spontaneous healing capacity of cartilage is limited. On October 5, 2009 ChondroCelect received European marketing authorisation as the first Advanced Therapy Medicinal Product, indicated for repair of single symptomatic cartilage defects of the femoral condyle of the knee (International Cartilage Repair Society [ICRS] grade III or IV) in adults.

About MedInvents

MedInvents NV is a Belgian ISO certified company, established in 2004 to investigate, develop, manufacture and distribute new and innovative applications with accessories mainly in the field of cancer diagnostics. The Spirotome and Coramate are diagnostic macro biopsy systems, based on a well controlled, direct and frontal biopsy technology with minimal invasion and optimal patient care. The products are CE and FDA approved for 13 clinical applications. These biopsy tools make the bridge between molecular biology laboratories and patient through high quality, representative and comfortable tissue harvest. With TiGenix, MedInvents entered the therapeutic orthopedic field in 2009.

Forward-looking information

This document contains forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.